AN2 Therapeutics, Inc. Research and Development Expense
AN2 Therapeutics, Inc. (ANTX) reported Research and Development Expense of $6.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- AN2 Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $6.02M, a 88.09% increase year-over-year.
- AN2 Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $6.74M, a 12.31% decline year-over-year.
- AN2 Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $6.88M, a 27.46% increase year-over-year.
- AN2 Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $7.00M, a 15.53% decline year-over-year.
- AN2 Therapeutics, Inc. research and development expense for fiscal 2025 was $24.77M, a 38.82% decline from fiscal 2024.
- AN2 Therapeutics, Inc. research and development expense for fiscal 2024 was $40.49M, a 26.21% decline from fiscal 2023.
- AN2 Therapeutics, Inc. research and development expense for fiscal 2023 was $54.87M, a 92.46% increase from fiscal 2022.
- AN2 Therapeutics, Inc. research and development expense for fiscal 2022 was $28.51M, a 76.47% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.02M 10-Q · filed 2026-08-11 | $12.76M 10-Q · filed 2026-08-11 | $19.64M derived: sum of 3 quarters · filed 2026-08-11 | $26.64M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $6.74M 10-Q · filed 2026-05-11 | $13.62M derived: sum of 2 quarters · filed 2026-05-11 | $20.62M derived: sum of 3 quarters · filed 2026-05-11 | $23.82M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $6.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $13.88M derived: sum of 2 quarters · filed 2026-03-17 | $17.08M derived: sum of 3 quarters · filed 2026-08-11 | $24.77M 10-K · filed 2026-03-17 |
| 2025-09-30 | $7.00M 10-Q · filed 2025-11-12 | $10.20M derived: sum of 2 quarters · filed 2026-08-11 | $17.89M 10-Q · filed 2025-11-12 | $23.29M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $3.20M 10-Q · filed 2026-08-11 | $10.89M 10-Q · filed 2026-08-11 | $16.29M derived: sum of 3 quarters · filed 2026-08-11 | $24.57M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $7.69M 10-Q · filed 2026-05-11 | $13.09M derived: sum of 2 quarters · filed 2026-05-11 | $21.37M derived: sum of 3 quarters · filed 2026-05-11 | $33.52M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $13.68M derived: sum of 2 quarters · filed 2026-03-17 | $25.83M derived: sum of 3 quarters · filed 2026-03-17 | $40.49M 10-K · filed 2026-03-17 |
| 2024-09-30 | $8.29M 10-Q · filed 2025-11-12 | $20.44M derived: sum of 2 quarters · filed 2025-11-12 | $35.09M 10-Q · filed 2025-11-12 | $50.01M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $12.15M 10-Q · filed 2025-08-12 | $26.80M 10-Q · filed 2025-08-12 | $41.72M derived: sum of 3 quarters · filed 2025-08-12 | $56.15M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $14.65M 10-Q · filed 2025-05-13 | $29.57M derived: sum of 2 quarters · filed 2025-05-13 | $44.00M derived: sum of 3 quarters · filed 2025-05-13 | $57.54M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $14.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $29.35M derived: sum of 2 quarters · filed 2025-03-25 | $42.89M derived: sum of 3 quarters · filed 2025-03-25 | $54.87M 10-K · filed 2025-03-25 |
| 2023-09-30 | $14.43M 10-Q · filed 2024-11-13 | $27.97M derived: sum of 2 quarters · filed 2024-11-13 | $39.95M 10-Q · filed 2024-11-13 | $48.70M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $13.54M 10-Q · filed 2024-08-13 | $25.52M 10-Q · filed 2024-08-13 | $34.27M derived: sum of 3 quarters · filed 2024-08-13 | $41.70M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $11.98M 10-Q · filed 2024-05-14 | $20.74M derived: sum of 2 quarters · filed 2024-05-14 | $28.16M derived: sum of 3 quarters · filed 2024-05-14 | $34.86M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $8.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $16.18M derived: sum of 2 quarters · filed 2024-03-29 | $22.88M derived: sum of 3 quarters · filed 2024-03-29 | $28.51M 10-K · filed 2024-03-29 |
| 2022-09-30 | $7.43M 10-Q · filed 2023-11-09 | $14.13M derived: sum of 2 quarters · filed 2023-11-09 | $19.76M 10-Q · filed 2023-11-09 | $25.07M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $6.70M 10-Q · filed 2023-08-10 | $12.33M 10-Q · filed 2023-08-10 | $17.64M derived: sum of 3 quarters · filed 2023-08-10 | $22.99M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $5.63M 10-Q · filed 2023-05-11 | $10.95M derived: sum of 2 quarters · filed 2023-05-11 | $16.29M derived: sum of 3 quarters · filed 2023-05-11 | $20.14M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $5.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $10.66M derived: sum of 2 quarters · filed 2023-03-29 | $14.51M derived: sum of 3 quarters · filed 2023-03-29 | $16.16M 10-K · filed 2023-03-29 |
| 2021-09-30 | $5.34M 10-Q · filed 2022-11-09 | $9.20M derived: sum of 2 quarters · filed 2022-11-09 | $10.84M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $3.85M 10-Q · filed 2022-08-11 | $5.50M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $1.65M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |